

Federal Register Notice: 89 FR 51554, [Federal Register :: Networking and Information Technology Research and Development Request for Information on Digital Twins Research and Development](#), June 18, 2024.

## **Request for Information on the National Digital Twins R&D Strategic Plan**

Jason Hsu

**DISCLAIMER:** Please note that the RFI public responses received and posted do not represent the views or opinions of the U.S. Government. We bear no responsibility for the accuracy, legality, or content of the responses and external links included in this document.

Via FDMS

Jason Hsu, 7/27/2024

[REDACTED]

When Digital Twins techniques are applied to assess the efficacy of a new medical treatment relative to a control (a placebo or a Standard of Care), the FDA should be cautious in accepting claims of unbiasedness in the estimation, especially when such claims are based on Real-World Evidence (RWE) data instead of Randomized Controlled Trial (RCT) data. For example, using a Digital Twins technique to predict, for a patient given the new treatment, what the outcome would be had that patient been given the control requires deep statistical knowledge to overcome potential bias from a lack of randomization and/or noise in predictive covariates.